New blood thinner argatroban tested in heart stent patients
NCT ID NCT00508924
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested three doses of argatroban, a blood thinner, in 140 patients undergoing elective heart stent procedures. It compared argatroban to the standard blood thinner heparin, both given with clopidogrel and aspirin. The goal was to see how well argatroban prevents blood clots and bleeding complications during and after the procedure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Argatroban (a blood thinner) compared to heparin, both given with clopidogrel and aspirin
What this could lead to
If successful, argatroban could offer a safer or more effective blood-thinning option for patients undergoing heart stent procedures.
What could go wrong
This is an early phase 2 trial with only 140 participants, so results may not apply to all patients. Bleeding risks are a concern with any blood thinner.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
Aalst, Belgium
-
Study site
Bad Nauheim, Germany
-
Study site
Cologne, Germany
-
Study site
Dachau, Germany
-
Study site
Düren, Germany
-
Study site
Frankfurt, Germany
-
Study site
Halle, Germany
-
Study site
Mainz, Germany